These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 15496639)

  • 1. Effects of fluvoxamine on lansoprazole pharmacokinetics in relation to CYP2C19 genotypes.
    Yasui-Furukori N; Saito M; Uno T; Takahata T; Sugawara K; Tateishi T
    J Clin Pharmacol; 2004 Nov; 44(11):1223-9. PubMed ID: 15496639
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Different effects of fluvoxamine on rabeprazole pharmacokinetics in relation to CYP2C19 genotype status.
    Uno T; Shimizu M; Yasui-Furukori N; Sugawara K; Tateishi T
    Br J Clin Pharmacol; 2006 Mar; 61(3):309-14. PubMed ID: 16487224
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enantioselective disposition of lansoprazole in relation to CYP2C19 genotypes in the presence of fluvoxamine.
    Miura M; Tada H; Yasui-Furukori N; Uno T; Sugawara K; Tateishi T; Suzuki T
    Br J Clin Pharmacol; 2005 Jul; 60(1):61-8. PubMed ID: 15963095
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of clarithromycin on lansoprazole pharmacokinetics between CYP2C19 genotypes.
    Saito M; Yasui-Furukori N; Uno T; Takahata T; Sugawara K; Munakata A; Tateishi T
    Br J Clin Pharmacol; 2005 Mar; 59(3):302-9. PubMed ID: 15752376
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Different inhibitory effect of fluvoxamine on omeprazole metabolism between CYP2C19 genotypes.
    Yasui-Furukori N; Takahata T; Nakagami T; Yoshiya G; Inoue Y; Kaneko S; Tateishi T
    Br J Clin Pharmacol; 2004 Apr; 57(4):487-94. PubMed ID: 15025747
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic differences between the enantiomers of lansoprazole and its metabolite, 5-hydroxylansoprazole, in relation to CYP2C19 genotypes.
    Miura M; Tada H; Yasui-Furukori N; Uno T; Sugawara K; Tateishi T; Suzuki T
    Eur J Clin Pharmacol; 2004 Nov; 60(9):623-8. PubMed ID: 15448955
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of a single time-point for plasma lansoprazole measurement that adequately reflects area under the concentration-time curve.
    Niioka T; Yasui-Furukori N; Uno T; Sugawara K; Kaneko S; Tateishi T
    Ther Drug Monit; 2006 Jun; 28(3):321-5. PubMed ID: 16778714
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of aging on the relationship between the cytochrome P450 2C19 genotype and omeprazole pharmacokinetics.
    Ishizawa Y; Yasui-Furukori N; Takahata T; Sasaki M; Tateishi T
    Clin Pharmacokinet; 2005; 44(11):1179-89. PubMed ID: 16231968
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of clarithromycin on the enantioselective disposition of lansoprazole in relation to CYP2C19 genotypes.
    Miura M; Tada H; Yasui-Furukori N; Uno T; Sugawara K; Tateishi T; Suzuki T
    Chirality; 2005 Jun; 17(6):338-44. PubMed ID: 15856433
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the kinetic disposition of and serum gastrin change by lansoprazole versus rabeprazole during an 8-day dosing scheme in relation to CYP2C19 polymorphism.
    Ieiri I; Kishimoto Y; Okochi H; Momiyama K; Morita T; Kitano M; Morisawa T; Fukushima Y; Nakagawa K; Hasegawa J; Otsubo K; Ishizaki T
    Eur J Clin Pharmacol; 2001 Sep; 57(6-7):485-92. PubMed ID: 11699613
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of lansoprazole in Chinese healthy subjects in relation to CYP2C19 genotypes.
    Hu YR; Qiao HL; Kan QC
    Acta Pharmacol Sin; 2004 Aug; 25(8):986-90. PubMed ID: 15301728
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of three proton pump inhibitors in Chinese subjects in relation to the CYP2C19 genotype.
    Qiao HL; Hu YR; Tian X; Jia LJ; Gao N; Zhang LR; Guo YZ
    Eur J Clin Pharmacol; 2006 Feb; 62(2):107-12. PubMed ID: 16402242
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of clarithromycin and verapamil on rabeprazole pharmacokinetics between CYP2C19 genotypes.
    Shimizu M; Uno T; Yasui-Furukori N; Sugawara K; Tateishi T
    Eur J Clin Pharmacol; 2006 Aug; 62(8):597-603. PubMed ID: 16783561
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Theophylline pharmacokinetics are not altered by lansoprazole in CYP2C19 poor metabolizers.
    Ko JW; Jang IJ; Shin JG; Nam SK; Shin SG; Flockhart DA
    Clin Pharmacol Ther; 1999 Jun; 65(6):606-14. PubMed ID: 10391666
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Finasteride 1 mg has no inhibitory effect on omeprazole metabolism in extensive and poor metabolizers for CYP2C19 in Japanese.
    Yasumori T; Narita H; Matsuda T; Takubo T; Ogawa M; Ishii M; Hara K; Ishii Y; Okuyama K; Fujimoto G; Ochiai H; Kano A; Hasegawa S; Sato K; Taniguchi T
    Eur J Clin Pharmacol; 2006 Nov; 62(11):939-46. PubMed ID: 16953457
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CYP2C19 genotype status and intragastric pH during dosing with lansoprazole or rabeprazole.
    Adachi K; Katsube T; Kawamura A; Takashima T; Yuki M; Amano K; Ishihara S; Fukuda R; Watanabe M; Kinoshita Y
    Aliment Pharmacol Ther; 2000 Oct; 14(10):1259-66. PubMed ID: 11012469
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of high-dose lansoprazole on intragastic pH in subjects who are homozygous extensive metabolizers of cytochrome P4502C19.
    Furuta T; Shirai N; Xiao F; Ohashi K; Ishizaki T
    Clin Pharmacol Ther; 2001 Nov; 70(5):484-92. PubMed ID: 11719736
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low daily 10-mg and 20-mg doses of fluvoxamine inhibit the metabolism of both caffeine (cytochrome P4501A2) and omeprazole (cytochrome P4502C19).
    Christensen M; Tybring G; Mihara K; Yasui-Furokori N; Carrillo JA; Ramos SI; Andersson K; Dahl ML; Bertilsson L
    Clin Pharmacol Ther; 2002 Mar; 71(3):141-52. PubMed ID: 11907488
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enantioselective disposition of lansoprazole in extensive and poor metabolizers of CYP2C19.
    Kim KA; Shon JH; Park JY; Yoon YR; Kim MJ; Yun DH; Kim MK; Cha IJ; Hyun MH; Shin JG
    Clin Pharmacol Ther; 2002 Jul; 72(1):90-9. PubMed ID: 12152007
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of cytochrome P2C19 in R-warfarin pharmacokinetics and its interaction with omeprazole.
    Uno T; Sugimoto K; Sugawara K; Tateishi T
    Ther Drug Monit; 2008 Jun; 30(3):276-81. PubMed ID: 18520598
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.